1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recomendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs; 2013 update. Ann Rheum Dis 2013. DOI: 10.1136/annrheumdis-2013-204573
2. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013; 6 (51): 609–22. DOI:http:// dx.doi.org/ 10.14412/1995-4484-2013-609-22
3. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 69 (2): 2569–81. DOI:10.1002/art/27584
4. Balsa A, De Miguel E, Castillo C et al. Superiority of SDAI jver DAS 28 in assessment of remission in rheumatoid arthritis hatients using power Doppler ultrasonography as a gold standart. Rheumatology (Oxford) 2010; 49 (4): 683–90. DOI:10.1093/ rheumatology/ kep442.Epub 2010 Jan 4
5. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63 (3): 573–86. DOI: 10.1002/art.30129
6. Насонов Е.Л. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012; 51 (2): 1–24.
7. Van Dongen H, Van Aken J, Lard L et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56 (5): 1424–32. DOI: http://dx.doi.org/10.1002/art.22525
8. Wewers-de Boer K, Visser K, Heimans L et al. Remission induction therapy with methotrexate and prednisolone in patients with early rheumatoid and undifferentiated arthritis. (the IMPROVED study). Ann Rheum Dis 2012; 71 (9): 1472–7. DOI:10.1136/annrheumdos-2011-200736
9. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58 (1): 73–81. DOI:10.1002/ art.23144
10. Bykerk V, Rowe D, Thorne C et al. Increased remission rates in patients receiving early optimal doses of parenteral methotrexat vs other therapeutic strategies from a nationwade early rheumatoid cohort. Ann Rheum Dis 2010; 69 (Suppl. 3): 65.
11. Wasco MCM, Dasgupta A, Hubert H et al. Propensity-adjusted association of methotrexat with overall survival in rheumatoid arthritis. Arthritis Rheum 2012; 10: 3772.
12. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014; 6 (51): 609–22. DOI:http://dx.doi.org/10.14412/1995-4484-2014-8-26
13. O´Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369 (4): 307–18. DOI: 10.1056/NEJMoa1303006.Epub 2013 Jun 11
14. Sokka T, Pincus N. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374 (9688): 430–2. DOI:10.1016/S0140-6736(09)61432-X
15. Kawalec P, Mikrut A, Wisniewska N et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and metha-analiysis. Clin Rheumatol 2013; 32 (10): 1414–24. DOI:10.1007/s10067-013-2329-9
16. Klarenbeek NB, Van der Kooij SM, Guler-Yuksel M et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70 (2): 315–9. DOI:10.1136/ ard.2010.136556. Epub 2010 Nov 10
17. Weslake SL, Colebatch AN, Baird J et al. The effect of methotrexate jn cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology (Oxford) 2010; 49 (2): 295–307. D OI:10.1093/rheumatology/kep366.Epub 2009 Nov 27
18. Sandrini G, Proietti Cecchini A, Alfonsi E et al. The effectivenes of nimesulide in hain. A neurophysiological study in humans. Drugs of Today 2001; 37 (Suppl. B): 21–9.
19. Rabasseda X. Safety profile of nimesulide: ten years of clinical experience. Drugs of Today 1997; 33 (Suppl. 1): 41–50.

Р.М.Балабанова

ФГБУ НИИ ревматологии им. В.А.Насоновой РАН, Москва